Bei Akademie registrieren
UCB, BE0003739530

UCB stock highlights BIMZELX joint-response lead at Week 24

Published on 11/09/2026 at 17:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
UCB stock is in focus after BE BOLD results kept BIMZELX ahead of risankizumab at Week 24. The full findings are due Tuesday at ACR Convergence.

New data sharpen BIMZELX focus

  • UCB reported sustained numerical advantages for BIMZELX over risankizumab in the BE BOLD psoriatic arthritis study.
  • The complete Week 24 findings are scheduled for an oral presentation at ACR Convergence on Tuesday.
  • Safety and exploratory endpoints remain important factors for investors assessing the treatment's competitive position.
UCB, BE0003739530, Illustration mit AI erstellt.
UCB, BE0003739530, Illustration mit AI erstellt.

UCB released new Week 24 results from the BE BOLD head-to-head study on Monday, November 9, adding evidence for BIMZELX in psoriatic arthritis. In its November 9 press release, the company said 54.9% of patients receiving bimekizumab achieved an ACR50 response at Week 24, compared with 43.8% for risankizumab.

UCB stock traded at 299.30 euros on Lang & Schwarz at 17:49 CET on Monday, November 9.

Joint-response advantage continues

The Week 24 result extended the numerical lead recorded at Week 16, when ACR50 responses reached 49.1% with BIMZELX and 38.0% with risankizumab. The Week 16 result was the study's primary endpoint and showed statistically significant superiority for bimekizumab.

BE BOLD enrolled 553 adults with active psoriatic arthritis in a randomized, double-blind Phase 3b trial. Participants were either new to biologic treatment or had previously received one tumor necrosis factor inhibitor without adequate benefit or because of intolerance.

Secondary measures need scrutiny

UCB said responses were numerically higher for BIMZELX across secondary measures covering joint, skin and overall disease activity. The first ranked secondary endpoint, minimal disease activity at Week 16, was 3.4 percentage points higher with bimekizumab, but the difference was not statistically significant and sequential testing stopped at that point.

Skin clearance was more closely matched at Week 24. PASI100 was reached by 59.7% of bimekizumab-treated patients and 59.1% of those receiving risankizumab, without nominal statistical significance. Localized Candida infections occurred more often with bimekizumab, at 2.9% versus 0.7%; UCB said all were mild or moderate, with none serious or leading to discontinuation.

Presentation sets the next catalyst

The full Week 24 findings are scheduled for an oral presentation at ACR Convergence in Orlando at 10:15 a.m. Eastern Time on Tuesday, November 10. The program includes 18 abstracts across psoriatic arthritis, axial spondyloarthritis, rheumatoid arthritis and systemic lupus erythematosus.

UCB at a glance

  • Company: UCB S.A.
  • ISIN: BE0003739530
  • Stock: UCB on Euronext Brussels
  • Lang & Schwarz quote: 299.30 euros at 17:49 CET on November 9, 2026
  • Clinical program: BE BOLD Phase 3b study
  • Next event: Full Week 24 presentation on November 10, 2026

Belgian equities remain the broader setting for pharmaceutical shares; see Current market reports.

For more company developments, see More news and analyses on UCB stock.

Disclaimer...
en | BE0003739530 | UCB | boerse | 70482421 | bgmi